| Xencor (XNCR) Reports Q1 Loss, Tops Revenue Estimates |
Xencor (XNCR) came out with a quarterly loss of $0.66 per share versus the Zacks Consensus Estimate of a loss of $0.63. This compares to loss of $1.11 per share a year ago. |
zacks.com |
2025-05-07 22:30:35 |
Czytaj oryginał (ang.) |
| Xencor Reports First Quarter 2025 Financial Results |
PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today reported financial results for the first quarter ended March 31, 2025 and provided a review of recent business and program updates. “Recently presented interim Phase 1 results support XmAb942 as a high potency investigational anti-TL1A antibody and an every 12-week subcutaneous dosing regimen during. |
businesswire.com |
2025-05-07 20:01:00 |
Czytaj oryginał (ang.) |
| Will Xencor (XNCR) Report Negative Q1 Earnings? What You Should Know |
Xencor (XNCR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. |
zacks.com |
2025-05-01 15:06:20 |
Czytaj oryginał (ang.) |
| Xencor (XNCR) Upgraded to Buy: Here's Why |
Xencor (XNCR) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term. |
zacks.com |
2025-04-10 17:01:09 |
Czytaj oryginał (ang.) |
| Xencor (XNCR) Reports Q4 Loss, Tops Revenue Estimates |
Xencor (XNCR) came out with a quarterly loss of $0.62 per share versus the Zacks Consensus Estimate of a loss of $0.83. This compares to loss of $0.31 per share a year ago. |
zacks.com |
2025-02-27 12:15:27 |
Czytaj oryginał (ang.) |
| Xencor Reports Fourth Quarter and Full Year 2024 Financial Results |
PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today reported financial results for the fourth quarter and full year ended December 31, 2024 and provided clinical updates and priorities for 2025. “In 2024, we began rebalancing our pipeline to focus on XmAb® drug candidates that leverage our protein engineering strengths and reduce exposure to biologica. |
businesswire.com |
2025-02-27 10:01:00 |
Czytaj oryginał (ang.) |
| Down -21.69% in 4 Weeks, Here's Why Xencor (XNCR) Looks Ripe for a Turnaround |
Xencor (XNCR) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock. |
zacks.com |
2025-01-21 12:36:09 |
Czytaj oryginał (ang.) |
| After Plunging -20.27% in 4 Weeks, Here's Why the Trend Might Reverse for Xencor (XNCR) |
Xencor (XNCR) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock. |
zacks.com |
2025-01-20 12:40:22 |
Czytaj oryginał (ang.) |
| Here's Why Xencor (XNCR) is Poised for a Turnaround After Losing -23.68% in 4 Weeks |
The heavy selling pressure might have exhausted for Xencor (XNCR) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal. |
zacks.com |
2025-01-15 12:36:16 |
Czytaj oryginał (ang.) |
| Xencor (XNCR) Upgraded to Strong Buy: Here's What You Should Know |
Xencor (XNCR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy). |
zacks.com |
2025-01-14 15:00:36 |
Czytaj oryginał (ang.) |
| All You Need to Know About Xencor (XNCR) Rating Upgrade to Buy |
Xencor (XNCR) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term. |
zacks.com |
2024-12-12 15:06:13 |
Czytaj oryginał (ang.) |
| Wall Street Analysts Think Xencor (XNCR) Could Surge 31.58%: Read This Before Placing a Bet |
The average of price targets set by Wall Street analysts indicates a potential upside of 31.6% in Xencor (XNCR). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock. |
zacks.com |
2024-12-04 12:56:16 |
Czytaj oryginał (ang.) |
| Xencor to Participate at Upcoming Investor Conferences |
PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases, today announced that company management will participate at multiple upcoming investor conferences: Piper Sandler 36th Annual Healthcare Conference Date: Tuesday, December 3, 2024 Presentation Time: 2:00 p.m. ET / 11:00 a.m. PT Location: New York City 7th Annual Evercore HealthCONx Conference Date: Wedn. |
businesswire.com |
2024-11-26 18:01:00 |
Czytaj oryginał (ang.) |
| Xencor: Plamotamab NHL Data Leads To RA Program Advancement |
Xencor's Phase 1 data using Plamotamab for the treatment of relapsed/refractory Non-Hodgkin's Lymphoma patients, expected at ASH 2024 Annual Meeting December 9th of 2024 at 6:00 to 8:00. Initiation of the phase 1b/2a study, using Plamotamab for the treatment of patients with multi-drug resistant Rheumatoid Arthritis, expected 1st half of 2025. XmAb657 is a long-acting CD19 X CD3 bispecific antibody being developed to target patients with autoimmune disorders; Phase 1 trial initiation for this program expected 2nd half of 2025. |
seekingalpha.com |
2024-11-22 16:00:53 |
Czytaj oryginał (ang.) |
| Wall Street Analysts Believe Xencor (XNCR) Could Rally 53.53%: Here's is How to Trade |
The average of price targets set by Wall Street analysts indicates a potential upside of 53.5% in Xencor (XNCR). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock. |
zacks.com |
2024-11-18 13:00:41 |
Czytaj oryginał (ang.) |
| Xencor (XNCR)'s Technical Outlook is Bright After Key Golden Cross |
From a technical perspective, Xencor, Inc. (XNCR) is looking like an interesting pick, as it just reached a key level of support. XNCR's 50-day simple moving average crossed above its 200-day simple moving average, which is known as a "golden cross" in the trading world. |
zacks.com |
2024-11-14 12:56:09 |
Czytaj oryginał (ang.) |
| Xencor (XNCR) Reports Q3 Loss, Tops Revenue Estimates |
Xencor (XNCR) came out with a quarterly loss of $0.71 per share versus the Zacks Consensus Estimate of a loss of $0.98. This compares to loss of $0.40 per share a year ago. |
zacks.com |
2024-11-06 20:21:13 |
Czytaj oryginał (ang.) |
| Xencor Reports Third Quarter 2024 Financial Results |
PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases, today reported financial results for the third quarter ended September 30, 2024 and provided a review of recent business and clinical-stage program updates. “In September, we provided updates across our clinical pipeline of XmAb® bispecific T-cell engagers in oncology and introduced our new autoimmune p. |
businesswire.com |
2024-11-06 18:01:00 |
Czytaj oryginał (ang.) |
| Xencor Doses First Subject in Phase 1/2 Study of XmAb®942 in Development for Patients with Inflammatory Bowel Disease |
PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases, today announced that it has initiated dosing of healthy volunteers in the first-in-human study of XmAb®942, an investigational high-potency extended half-life anti-TL1A antibody. Xencor continues to expect initial data from the ongoing study during the first half of 2025. “An anti-TL1A antibody enginee. |
businesswire.com |
2024-11-04 09:00:00 |
Czytaj oryginał (ang.) |
| Does Xencor (XNCR) Have the Potential to Rally 68.16% as Wall Street Analysts Expect? |
The average of price targets set by Wall Street analysts indicates a potential upside of 68.2% in Xencor (XNCR). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock. |
zacks.com |
2024-11-01 12:56:09 |
Czytaj oryginał (ang.) |
| Xencor (XNCR) Expected to Beat Earnings Estimates: Should You Buy? |
Xencor (XNCR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. |
zacks.com |
2024-10-29 13:06:10 |
Czytaj oryginał (ang.) |
| Wall Street Analysts Predict a 67.2% Upside in Xencor (XNCR): Here's What You Should Know |
The average of price targets set by Wall Street analysts indicates a potential upside of 67.2% in Xencor (XNCR). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock. |
zacks.com |
2024-10-16 14:55:39 |
Czytaj oryginał (ang.) |
| Xencor Announces Upcoming Change to Board of Directors |
PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases, today announced that Dagmar Rosa-Bjorkeson has informed the Company that she will not stand for reelection to the Company's Board of Directors at the 2025 Annual Meeting of Stockholders. Ms. Rosa-Bjorkeson has served as a director since 2019 and plans to pursue another business opportunity. Xencor will. |
businesswire.com |
2024-10-04 12:01:00 |
Czytaj oryginał (ang.) |
| Xencor Announces Closing of Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares |
PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (“Xencor”) (Nasdaq: XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases, today announced the closing of its previously announced underwritten public offering of 8,093,712 shares of its common stock at a price to the public of $18.00 per share, which includes the exercise in full by the underwriters of their option to purchase up to 1,458,600 additional shares of. |
businesswire.com |
2024-09-12 20:01:00 |
Czytaj oryginał (ang.) |
| Xencor: Vudalimab Development Along With Hidden Gem Candidate |
Monotherapy and combination dose cohort data from the phase 2 study, using vudalimab for the treatment of patients with mCRPC, expected 1st half of 2025. The global metastatic castrate-resistant prostate cancer treatment market size is projected to reach $20.70 billion by 2031. XmAb942 is a candidate in the company's pipeline which has the potential to become the best in class anti-TL1A inhibitor for the treatment of autoimmune disorders like UC and CD. |
seekingalpha.com |
2024-09-12 12:16:46 |
Czytaj oryginał (ang.) |
| Xencor (XNCR) Surges 10.5%: Is This an Indication of Further Gains? |
Xencor (XNCR) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road. |
zacks.com |
2024-09-12 09:55:43 |
Czytaj oryginał (ang.) |
| Xencor Stock Gains 23% on Encouraging Pipeline Advancements |
XNCR moves four new XmAb drug development programs for autoimmune diseases. It also provided favorable updates for two of its oncology drug candidates. |
zacks.com |
2024-09-10 17:25:22 |
Czytaj oryginał (ang.) |
| Xencor Announces XmAb Drug Candidates in Autoimmune Disease with Near-Term Clinical Plans and Shares Clinical Progress in Early-Stage Oncology Programs |
PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases, today announced four new XmAb® programs in development for the treatment of patients with autoimmune diseases and provided updates from dose-escalation studies evaluating its first-in-class oncology programs, including XmAb819 (ENPP3 x CD3) in patients with advanced clear cell renal cell carcinoma and. |
businesswire.com |
2024-09-09 11:31:00 |
Czytaj oryginał (ang.) |
| Xencor (XNCR) Reports Q2 Loss, Misses Revenue Estimates |
Xencor (XNCR) came out with a quarterly loss of $1.07 per share versus the Zacks Consensus Estimate of a loss of $0.85. This compares to loss of $0.37 per share a year ago. |
zacks.com |
2024-08-05 22:15:36 |
Czytaj oryginał (ang.) |
| Xencor Regains CD20 x CD3 Bispecific T-Cell Engager |
PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases, announced it will regain exclusive worldwide rights to plamotamab, a CD20 x CD3 bispecific T-cell engager, which Xencor advanced through Phase 1 clinical development in hematologic cancers. In 2021, Xencor entered a collaboration and license agreement with Janssen Biotech, Inc. to develop and commercial. |
businesswire.com |
2024-06-13 12:01:00 |
Czytaj oryginał (ang.) |